x
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934 for the Quarter Ended July 1,
2006
|
o
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934
|
Delaware
|
04-2209186
|
(State
of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
|
|
81
Wyman Street, P.O. Box 9046
|
|
Waltham,
Massachusetts
|
02454-9046
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Class
|
|
Outstanding
at July 28, 2006
|
||
Common
Stock, $1.00 par value
|
|
157,593,971
|
|
July 1, |
December
31,
|
|||||
(In
thousands)
|
2006
|
2005
|
|||||
Current
Assets:
|
|||||||
Cash and cash equivalents
|
$
|
189,716
|
$
|
214,326
|
|||
Short-term available-for-sale investments, at quoted market value
(amortized cost of $8,267 and $80,661)
|
8,267
|
80,661
|
|||||
Accounts receivable, less allowances of $22,548 and
$21,841
|
544,520
|
565,564
|
|||||
Inventories:
|
|||||||
Raw materials and supplies
|
150,543
|
133,774
|
|||||
Work in process
|
56,896
|
50,043
|
|||||
Finished goods
|
188,721
|
175,575
|
|||||
Deferred tax assets
|
80,487
|
79,586
|
|||||
Other current assets
|
61,072
|
54,371
|
|||||
1,280,222
|
1,353,900
|
||||||
Property,
Plant and Equipment, at Cost
|
541,852
|
515,385
|
|||||
Less: Accumulated depreciation and amortization
|
258,610
|
234,731
|
|||||
283,242
|
280,654
|
||||||
Acquisition-related
Intangible Assets
|
405,011
|
450,740
|
|||||
Other
Assets
|
216,907
|
200,080
|
|||||
Goodwill
|
1,990,821
|
1,966,195
|
|||||
$
|
4,176,203
|
$
|
4,251,569
|
|
July 1, |
December
31,
|
|||||
(In
thousands except share amounts)
|
2006
|
2005
|
|||||
Current
Liabilities:
|
|||||||
Short-term obligations and current maturities of long-term
obligations
|
$
|
171,540
|
$
|
130,137
|
|||
Accounts payable
|
147,635
|
153,475
|
|||||
Accrued payroll and employee benefits
|
98,199
|
114,707
|
|||||
Accrued income taxes
|
21,860
|
55,147
|
|||||
Deferred revenue
|
101,913
|
85,592
|
|||||
Customer deposits
|
39,342
|
38,229
|
|||||
Accrued warranty costs (Note 10)
|
36,326
|
33,453
|
|||||
Other
accrued expenses (Notes 2 and 11)
|
167,139
|
180,922
|
|||||
783,954
|
791,662
|
||||||
Deferred
Income Taxes
|
43,468
|
65,015
|
|||||
Other
Long-term Liabilities
|
144,313
|
132,950
|
|||||
Long-term
Obligations:
|
|||||||
Senior notes (Note 9)
|
379,529
|
380,542
|
|||||
Subordinated convertible obligations
|
77,234
|
77,234
|
|||||
Other
|
10,699
|
10,854
|
|||||
467,462
|
468,630
|
||||||
Shareholders’
Equity:
|
|||||||
Preferred stock, $100 par value, 50,000 shares authorized; none
issued
|
|||||||
Common stock, $1 par value, 350,000,000 shares authorized; 183,154,779
and
181,817,452 shares issued
|
183,155
|
181,817
|
|||||
Capital in excess of par value
|
1,459,872
|
1,421,382
|
|||||
Retained earnings
|
1,699,261
|
1,604,475
|
|||||
Treasury stock at cost, 25,597,876 and 19,335,163 shares
|
(666,120
|
)
|
(437,707
|
)
|
|||
Deferred compensation
|
—
|
(3,834
|
)
|
||||
Accumulated other comprehensive items (Note 6)
|
60,838
|
27,179
|
|||||
2,737,006
|
2,793,312
|
||||||
$
|
4,176,203
|
$
|
4,251,569
|
Three
Months Ended
|
|||||||
July
1,
|
July
2,
|
||||||
(In thousands except per share amounts) | 2006 | 2005 | |||||
Revenues
|
$
|
713,468
|
$
|
653,621
|
|||
Costs
and Operating Expenses:
|
|||||||
Cost
of revenues
|
388,976
|
366,166
|
|||||
Selling,
general and administrative expenses
|
206,919
|
192,593
|
|||||
Research
and development expenses
|
40,620
|
39,432
|
|||||
Restructuring
and other costs, net (Note 11)
|
4,780
|
2,216
|
|||||
641,295
|
600,407
|
||||||
Operating
Income
|
72,173
|
53,214
|
|||||
Other
Income (Expense), Net (Note 4)
|
(3,383
|
)
|
25,504
|
||||
Income from Continuing Operations Before Provision for Income Taxes
|
68,790
|
78,718
|
|||||
Provision
for Income Taxes
|
(19,847
|
)
|
(21,958
|
)
|
|||
Income
from Continuing Operations
|
48,943
|
56,760
|
|||||
Gain (Loss) on Disposal of Discontinued Operations (includes income
tax
benefit of $623 in 2006, net of
income tax provision of $2,034 in 2005; Note 13)
|
(1,063
|
)
|
3,463
|
||||
Net
Income
|
$
|
47,880
|
$
|
60,223
|
|||
Earnings per Share from Continuing Operations (Note 5):
|
|||||||
Basic
|
$
|
.30
|
$
|
.35
|
|||
Diluted
|
$
|
.30
|
$
|
.35
|
|||
Earnings
per Share (Note 5):
|
|||||||
Basic
|
$
|
.30
|
$
|
.37
|
|||
Diluted
|
$
|
.29
|
$
|
.37
|
|||
Weighted
Average Shares (Note 5):
|
|||||||
Basic
|
161,289
|
161,255
|
|||||
Diluted
|
165,523
|
164,658
|
Six
Months Ended
|
|||||||
July 1, | July 2, | ||||||
(In thousands except per share amounts) | 2006 | 2005 | |||||
Revenues
|
$
|
1,397,755
|
$
|
1,212,829
|
|||
Costs
and Operating Expenses:
|
|||||||
Cost
of revenues
|
760,639
|
666,140
|
|||||
Selling,
general and administrative expenses
|
409,367
|
356,094
|
|||||
Research
and development expenses
|
79,357
|
75,760
|
|||||
Restructuring
and other costs, net (Note 11)
|
8,374
|
1,945
|
|||||
1,257,737
|
1,099,939
|
||||||
Operating
Income
|
140,018
|
112,890
|
|||||
Other
Income (Expense), Net (Note 4)
|
(7,162
|
)
|
28,808
|
||||
Income from Continuing Operations Before Provision for Income Taxes
|
132,856
|
141,698
|
|||||
Provision
for Income Taxes
|
(40,294
|
)
|
(39,355
|
)
|
|||
Income
from Continuing Operations
|
92,562
|
102,343
|
|||||
Gain on Disposal of Discontinued Operations, Net (net of income tax
provision of $1,303 and $4,272; Note 13)
|
2,224
|
6,736
|
|||||
Net
Income
|
$
|
94,786
|
$
|
109,079
|
|||
Earnings per Share from Continuing Operations (Note 5):
|
|||||||
Basic
|
$
|
.57
|
$
|
.64
|
|||
Diluted
|
$
|
.56
|
$
|
.63
|
|||
Earnings
per Share (Note 5):
|
|||||||
Basic
|
$
|
.58
|
$
|
.68
|
|||
Diluted
|
$
|
.57
|
$
|
.67
|
|||
Weighted
Average Shares (Note 5):
|
|||||||
Basic
|
162,167
|
161,106
|
|||||
Diluted
|
166,253
|
164,694
|
Six
Months Ended
|
|||||||
July 1, | July 2, | ||||||
(In thousands) | 2006 | 2005 | |||||
Operating
Activities:
|
|||||||
Net
income
|
$
|
94,786
|
$
|
109,079
|
|||
Gain on disposal of discontinued operations, net
|
(2,224
|
)
|
(6,736
|
)
|
|||
Income from continuing operations
|
92,562
|
102,343
|
|||||
Adjustments to reconcile income from continuing operations to net
cash
provided by operating
activities:
|
|||||||
Depreciation and amortization
|
76,437
|
47,435
|
|||||
Change in deferred income taxes
|
(10,703
|
)
|
(1,438
|
)
|
|||
Gain on sale of product lines, net
|
(207
|
)
|
(119
|
)
|
|||
Gain on investments, net
|
(525
|
)
|
(32,066
|
)
|
|||
Noncash equity compensation
|
12,937
|
1,339
|
|||||
Other noncash expenses, net
|
1,096
|
13,513
|
|||||
Changes in current accounts, excluding the effects of acquisitions
and
dispositions:
|
|||||||
Accounts receivable
|
36,601
|
6,154
|
|||||
Inventories
|
(28,440
|
)
|
(15,200
|
)
|
|||
Other current assets
|
(3,796
|
)
|
2,303
|
||||
Accounts payable
|
(11,691
|
)
|
(11,521
|
)
|
|||
Other current liabilities
|
(64,525
|
)
|
(22,187
|
)
|
|||
Net
cash provided by continuing operations
|
99,746
|
90,556
|
|||||
Net
cash used in discontinued operations
|
(1,528
|
)
|
(1,577
|
)
|
|||
Net
cash provided by operating activities
|
98,218
|
88,979
|
|||||
Investing
Activities:
|
|||||||
Acquisitions,
net of cash acquired
|
(26,574
|
)
|
(914,923
|
)
|
|||
Proceeds
from sale of available-for-sale investments
|
151,012
|
349,863
|
|||||
Purchases
of available-for-sale investments
|
(77,850
|
)
|
(148,450
|
)
|
|||
Purchases
of property, plant and equipment
|
(21,800
|
)
|
(16,441
|
)
|
|||
Proceeds
from sale of property, plant and equipment
|
2,071
|
9,534
|
|||||
Proceeds
from sale of product lines
|
8,875
|
5,661
|
|||||
Collection
of notes receivable
|
2,805
|
—
|
|||||
Proceeds
from sale of other investments
|
816
|
280
|
|||||
Increase
in other assets
|
(8,481
|
)
|
(1,535
|
)
|
|||
Other
|
(546
|
)
|
(64
|
)
|
|||
Net
cash provided by (used in) continuing operations
|
30,328
|
(716,075
|
)
|
||||
Net
cash provided by discontinued operations
|
5,333
|
5,327
|
|||||
Net
cash provided by (used in) investing activities
|
$
|
35,661
|
$
|
(710,748
|
)
|
Six
Months Ended
|
|||||||
July 1, | July 2, | ||||||
(In thousands) | 2006 | 2005 |
Financing
Activities:
|
|||||||
Purchases of company common stock
|
$
|
(228,001
|
)
|
$
|
—
|
||
Net
proceeds from issuance of long-term debt
|
—
|
247,450
|
|||||
Increase
in
short-term notes payable
|
36,664
|
219,150
|
|||||
Net proceeds from issuance of company common stock
|
22,072
|
8,721
|
|||||
Borrowings under short-term bridge financing agreement
|
—
|
570,000
|
|||||
Repayment of bridge financing agreement
|
—
|
(570,000
|
)
|
||||
Tax benefits from exercised stock options (Note 7)
|
5,589
|
—
|
|||||
Other
|
(38
|
)
|
(2,161
|
)
|
|||
Net
cash provided by (used in) financing activities
|
(163,714
|
)
|
473,160
|
||||
Exchange
Rate Effect on Cash of Continuing Operations
|
5,225
|
(18,533
|
)
|
||||
Decrease
in Cash and Cash Equivalents
|
(24,610
|
)
|
(167,142
|
)
|
|||
Cash
and Cash Equivalents at Beginning of Period
|
214,326
|
326,886
|
|||||
Cash
and Cash Equivalents at End of Period
|
$
|
189,716
|
$
|
159,744
|
|||
Noncash
Investing Activities:
|
|||||||
Fair
value of assets of acquired businesses
|
$
|
37,527
|
$
|
1,076,315
|
|||
Cash
paid for acquired businesses
|
(28,005
|
)
|
(920,135
|
)
|
|||
Liabilities
of acquired businesses
|
$
|
9,522
|
$
|
156,180
|
1.
|
General
|
2.
|
Merger
and Acquisitions
|
2.
|
Merger
and Acquisitions (continued)
|
(In thousands) | EGS | Other | Total | |||||||
Purchase
Price:
|
||||||||||
Cash
paid (a)
|
$
|
25,363
|
$
|
2,642
|
$
|
28,005
|
||||
Cash
acquired
|
(1,417
|
)
|
(14
|
)
|
(1,431
|
)
|
||||
Purchase
price payable
|
2,343
|
91
|
2,434
|
|||||||
$
|
26,289
|
$
|
2,719
|
$
|
29,008
|
|||||
Allocation:
|
||||||||||
Current
assets
|
$
|
8,381
|
$
|
14
|
$
|
8,395
|
||||
Property,
plant and equipment
|
768
|
16
|
784
|
|||||||
Acquired
intangible assets (b)
|
—
|
2,857
|
2,857
|
|||||||
Goodwill
|
22,431
|
844
|
23,275
|
|||||||
Other
assets
|
785
|
—
|
785
|
|||||||
Liabilities
assumed
|
(6,076
|
)
|
(1,012
|
)
|
(7,088
|
)
|
||||
$
|
26,289
|
$
|
2,719
|
$
|
29,008
|
(a) |
Includes
transaction costs.
|
(b) |
The
acquired intangible assets for EGS will be determined in the third
quarter
of 2006, following finalization of the purchase price
allocation.
|
Customer
Relationships
|
$
|
446
|
||
Product
Technology
|
2,411
|
|||
$
|
2,857
|
2.
|
Merger
and Acquisitions (continued)
|
Three
Months Ended
|
Six
Months Ended
|
||||||
(In thousands except per share amounts) |
July
2, 2005
|
July
2, 2005
|
|||||
Revenues
|
$
|
688,080
|
$
|
1,341,148
|
|||
Net
Income
|
$
|
54,880
|
$
|
97,463
|
|||
Earnings per Share from Continuing Operations:
|
|||||||
Basic
|
$
|
.32
|
$
|
.56
|
|||
Diluted
|
$
|
.31
|
$
|
.56
|
|||
Earnings
Per Share:
|
|||||||
Basic
|
$
|
.34
|
$
|
.60
|
|||
Diluted
|
$
|
.34
|
$
|
.60
|
(In thousands) |
Severance
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
|||||||||
Balance
at December 31, 2005
|
$
|
2,494
|
$
|
345
|
$
|
73
|
$
|
2,912
|
|||||
Reserves
established
|
3,213
|
479
|
629
|
4,321
|
|||||||||
Payments
|
(1,636
|
)
|
(76
|
)
|
—
|
(1,712
|
)
|
||||||
Decrease
recorded as a reduction in goodwill
|
(415
|
)
|
—
|
(488
|
)
|
(903
|
)
|
||||||
Currency
translation
|
314
|
20
|
5
|
339
|
|||||||||
Balance
at July
1, 2006
|
$
|
3,970
|
$
|
768
|
$
|
219
|
$
|
4,957
|
2.
|
Merger
and Acquisitions (continued)
|
(In
thousands)
|
Severance
|
Abandonment
of
Excess
Facilities
|
Total
|
|||||||
Balance
at December 31, 2005
|
$
|
139
|
$
|
3,212
|
$
|
3,351
|
||||
Payments
|
—
|
(1,145
|
)
|
(1,145
|
)
|
|||||
Divestiture
|
—
|
(199
|
)
|
(199
|
)
|
|||||
Decrease
recorded as a reduction in goodwill
|
(15
|
)
|
(29
|
)
|
(44
|
)
|
||||
Currency
translation
|
9
|
185
|
194
|
|||||||
Balance
at July
1, 2006
|
$
|
133
|
$
|
2,024
|
$
|
2,157
|
3.
|
Business
Segment Information
|
Life
and
Laboratory
Sciences
|
Measurement
and Control
|
Eliminations
and
Other
|
Corporate
|
Total
|
||||||||||||||
(In
thousands)
|
||||||||||||||||||
Three
Months Ended July 1, 2006
|
||||||||||||||||||
Revenues
|
$
|
539,286
|
$
|
174,182
|
$
|
—
|
$
|
—
|
$
|
713,468
|
||||||||
Adjusted
operating income (a)
|
$
|
93,398
|
$
|
24,736
|
$
|
(3,512
|
)
|
$
|
(10,748
|
)
|
$
|
103,874
|
(b)
|
|
||||
Cost
of revenues charges
|
1,266
|
—
|
—
|
—
|
1,266
|
|||||||||||||
Restructuring
and other items
|
2,571
|
2,094
|
7
|
108
|
4,780
|
|||||||||||||
Stock
option compensation expense
|
2,808
|
704
|
(3,512
|
)
|
—
|
—
|
||||||||||||
Amortization
|
24,197
|
1,456
|
—
|
2
|
25,655
|
|||||||||||||
Operating
income
|
62,556
|
20,482
|
(7
|
)
|
(10,858
|
)
|
72,173
|
(b)
|
|
|||||||||
Other
expense, net
|
(3,383
|
)
|
||||||||||||||||
Income from continuing operations before provision for
income taxes
|
$
|
68,790
|
||||||||||||||||
Depreciation
|
$
|
9,656
|
$
|
2,222
|
$
|
—
|
$
|
1,584
|
$
|
13,462
|
3.
|
Business
Segment Information
(continued)
|
Life
and
Laboratory
Sciences
|
Measurement
and Control
|
Eliminations
and
Other
|
Corporate
|
Total
|
||||||||||||||
(In
thousands)
|
||||||||||||||||||
Three
Months Ended July 2, 2005
|
||||||||||||||||||
Revenues
|
$
|
487,462
|
$
|
166,159
|
$
|
—
|
$
|
—
|
$
|
653,621
|
||||||||
Adjusted
operating income (a)
|
$
|
77,920
|
$
|
15,829
|
$
|
—
|
$
|
(7,745
|
)
|
$
|
86,004
|
(c)
|
|
|||||
Cost
of revenues charges
|
11,232
|
233
|
—
|
—
|
11,465
|
|||||||||||||
Restructuring
and other items
|
(160
|
)
|
2,168
|
(502
|
)
|
710
|
2,216
|
|||||||||||
Amortization
|
17,773
|
1,335
|
—
|
1
|
19,109
|
|||||||||||||
Operating
income
|
49,075
|
12,093
|
502
|
(8,456
|
)
|
53,214
|
(c)
|
|
||||||||||
Other
income, net
|
25,504
|
|||||||||||||||||
Income from continuing operations before provision for
income
taxes
|
$
|
78,718
|
||||||||||||||||
Depreciation
|
$
|
7,764
|
$
|
2,045
|
$
|
—
|
$
|
951
|
$
|
10,760
|
||||||||
Six
Months Ended July 1, 2006
|
||||||||||||||||||
Revenues
|
$
|
1,051,641
|
$
|
346,114
|
$
|
—
|
$
|
—
|
$
|
1,397,755
|
||||||||
Adjusted
operating income (a)
|
$
|
179,548
|
$
|
49,135
|
$
|
(6,407
|
)
|
$
|
(21,402
|
)
|
$
|
200,874
|
(b)
|
|
||||
Cost
of revenues charges
|
1,266
|
—
|
—
|
—
|
1,266
|
|||||||||||||
Restructuring
and other items
|
5,617
|
2,634
|
9
|
114
|
8,374
|
|||||||||||||
Stock
option compensation expense
|
5,060
|
1,347
|
(6,407
|
)
|
—
|
—
|
||||||||||||
Amortization
|
48,292
|
2,920
|
—
|
4
|
51,216
|
|||||||||||||
Operating
income
|
119,313
|
42,234
|
(9
|
)
|
(21,520
|
)
|
140,018
|
(b)
|
|
|||||||||
Other
expense, net
|
(7,162
|
)
|
||||||||||||||||
Income from continuing operations before provision for
income taxes
|
$
|
132,856
|
||||||||||||||||
Depreciation
|
$
|
17,589
|
$
|
4,347
|
$
|
—
|
$
|
3,285
|
$
|
25,221
|
||||||||
3.
|
Business
Segment Information
(continued)
|
Life
and
Laboratory
Sciences
|
Measurement
and Control
|
Eliminations
and Other
|
Corporate
|
Total
|
||||||||||||||
(In
thousands)
|
||||||||||||||||||
Six
Months Ended July 2, 2005
|
||||||||||||||||||
Revenues
|
$
|
880,767
|
$
|
332,062
|
$
|
—
|
$
|
—
|
$
|
1,212,829
|
||||||||
Adjusted
operating income (a)
|
$
|
134,630
|
$
|
36,022
|
$
|
—
|
$
|
(17,829
|
)
|
$
|
152,823
|
(c)
|
|
|||||
Cost
of revenues charges
|
11,232
|
233
|
—
|
—
|
11,465
|
|||||||||||||
Restructuring
and other items
|
(1,894
|
)
|
3,202
|
(573
|
)
|
1,210
|
1,945
|
|||||||||||
Amortization
|
24,387
|
2,134
|
—
|
2
|
26,523
|
|||||||||||||
Operating
income
|
100,905
|
30,453
|
573
|
(19,041
|
)
|
112,890
|
(c)
|
|
||||||||||
Other
income, net
|
28,808
|
|||||||||||||||||
Income from continuing operations before provision for
income taxes
|
$
|
141,698
|
||||||||||||||||
Depreciation
|
$
|
14,543
|
$
|
4,461
|
$
|
—
|
$
|
1,908
|
$
|
20,912
|
(a)
|
Represents
operating income before restructuring and other costs, net; amortization
of acquisition-related intangibles; and, for the segments, stock
option
compensation expense.
|
(b)
|
Consolidated
adjusted operating income and consolidated operating income in the
second
quarter of 2006 include pre-tax stock option compensation expense
of $6.4
million, including $0.7 million in cost of revenues, $5.3 million
in
selling, general and administrative expenses and $0.4 million in
research
and development expenses. Consolidated adjusted operating income
and
consolidated operating income in the first six months of 2006 include
pre-tax stock option compensation expense of $11.8 million, including
$1.3
million in cost of revenues, $9.8 million in selling, general and
administrative expenses and $0.7 million in research and development
expenses. No stock option compensation expense has been capitalized
in
inventories due to immateriality.
|
(c)
|
Had
stock option expense been recorded in the second quarter of 2005,
consolidated adjusted operating income and consolidated operating
income
on a pro forma basis would have been lower by $5.1 million, including
$0.5
million in cost of revenues, $4.3 million in selling, general and
administrative expenses and $0.3 million in research and development
expenses. Had stock option expense been recorded in the first six
months
of 2005, consolidated adjusted operating income and consolidated
operating
income on a pro forma basis would have been lower by $10.5 million,
including $1.2 million in cost of revenues, $8.7 million in selling,
general and administrative expenses and $0.6 million in research
and
development expenses.
|
4.
|
Other
Income (Expense), Net
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
(In thousands) |
July 1,
2006
|
July
2,
2005
|
July
1,
2006
|
July
2,
2005
|
|||||||||
Interest
Income
|
$
|
3,393
|
$
|
2,591
|
$
|
6,925
|
$
|
5,927
|
|||||
Interest
Expense
|
(7,934
|
)
|
(7,287
|
)
|
(15,729
|
)
|
(10,442
|
)
|
|||||
Gain
on Investments, Net
|
560
|
29,802
|
525
|
32,066
|
|||||||||
Other
Items, Net
|
598
|
398
|
1,117
|
1,257
|
|||||||||
$
|
(3,383
|
)
|
$
|
25,504
|
$
|
(7,162
|
)
|
$
|
28,808
|
4.
|
Other
Income (Expense), Net (continued)
|
5.
|
Earnings
per Share
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
(In thousands except per share amounts) |
July 1,
2006
|
July
2,
2005
|
July
1,
2006
|
July
2,
2005
|
Income from Continuing Operations
|
$
|
48,943
|
$
|
56,760
|
$
|
92,562
|
$
|
102,343
|
|||||
Gain (Loss) on Disposal of Discontinued Operations
|
(1,063
|
)
|
3,463
|
2,224
|
6,736
|
||||||||
Net Income for Basic Earnings per Share
|
47,880
|
60,223
|
94,786
|
109,079
|
|||||||||
Effect
of Convertible Debentures
|
402
|
402
|
803
|
803
|
|||||||||
Income Available to Common Shareholders, as Adjusted for Diluted
Earnings
per Share
|
$
|
48,282
|
$
|
60,625
|
$
|
95,589
|
$
|
109,882
|
|||||
Basic
Weighted Average Shares
|
161,289
|
161,255
|
162,167
|
161,106
|
|||||||||
Effect
of:
|
|||||||||||||
Stock
options
|
2,318
|
1,515
|
2,171
|
1,704
|
|||||||||
Convertible
debentures
|
1,846
|
1,846
|
1,846
|
1,846
|
|||||||||
Restricted
stock awards and contingently issuable shares
|
70
|
42
|
69
|
38
|
|||||||||
Diluted Weighted Average Shares
|
165,523
|
164,658
|
166,253
|
164,694
|
|||||||||
Basic
Earnings per Share:
|
|||||||||||||
Continuing operations
|
$
|
.30
|
$
|
.35
|
$
|
.57
|
$
|
.64
|
|||||
Discontinued
operations
|
(.01
|
)
|
.02
|
.01
|
.04
|
||||||||
$
|
.30
|
$
|
.37
|
$
|
.58
|
$
|
.68
|
||||||
Diluted
Earnings per Share:
|
|||||||||||||
Continuing operations
|
$
|
.30
|
$
|
.35
|
$
|
.56
|
$
|
.63
|
|||||
Discontinued
operations
|
(.01
|
)
|
.02
|
.01
|
.04
|
||||||||
$
|
.29
|
$
|
.37
|
$
|
.57
|
$
|
.67
|
6.
|
Comprehensive
Income
|
7.
|
Stock-based
Compensation Plans and Stock-based Compensation
Expense
|
7.
|
Stock-based
Compensation Plans and Stock-based Compensation Expense
(continued)
|
Six
Months Ended
|
|||||||
July
1,
2006
|
July
2,
2005
|
||||||
Expected
Stock Price Volatility
|
28%
|
|
32%
|
|
|||
Risk
Free Interest Rate
|
4.7%
|
|
3.8%
|
|
|||
Expected
Life of Options (years)
|
4.5
|
4.3
|
|||||
Expected
Annual Dividend per Share
|
$
|
—
|
$
|
—
|
7.
|
Stock-based
Compensation Plans and Stock-based Compensation Expense
(continued)
|
Shares
(In
thousands)
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Term
(In
years)
|
Aggregate
Intrinsic
Value
(In
thousands)
|
||||||||||
Outstanding
at December 31, 2005
|
12,084
|
$
|
22.65
|
||||||||||
Granted
|
2,985
|
34.97
|
|||||||||||
Exercised
|
(1,181
|
)
|
18.68
|
||||||||||
Canceled
|
(131
|
)
|
29.22
|
||||||||||
Expired
|
(29
|
)
|
63.45
|
||||||||||
Outstanding
at July 1, 2006
|
13,728
|
25.58
|
4.7
|
$
|
158,026
|
||||||||
Vested
and Exercisable at July 1, 2006
|
6,723
|
21.85
|
3.2
|
$
|
102,452
|
Nonvested Restricted Share Awards |
Shares
|
Weighted
Average
Grant-Date
Fair
Value
|
|||||
Nonvested
at December 31, 2005
|
199,334
|
$
|
27.03
|
||||
Granted
|
27,500
|
34.31
|
|||||
Vested
|
(43,333
|
)
|
26.00
|
||||
Nonvested
at July 1, 2006
|
183,501
|
28.37
|
7.
|
Stock-based
Compensation Plans and Stock-based Compensation Expense
(continued)
|
Three
Months Ended
|
Six
Months Ended
|
||||||
(In thousands except per share amounts) |
July
2, 2005
|
July
2, 2005
|
|||||
Income
from Continuing Operations:
|
|||||||
As
reported
|
$
|
56,760
|
$
|
102,343
|
|||
Add: Stock-based employee compensation expense included in reported
results, net of tax
|
454
|
870
|
|||||
Deduct: Total stock-based employee compensation expense determined
under
the fair-
value-based method
for all awards, net of tax
|
(3,796
|
)
|
(7,678
|
)
|
|||
Pro
forma
|
$
|
53,418
|
$
|
95,535
|
|||
Basic
Earnings per Share from Continuing Operations:
|
|||||||
As
reported
|
$
|
.35
|
$
|
.64
|
|||
Pro
forma
|
$
|
.33
|
$
|
.59
|
|||
Diluted
Earnings per Share from Continuing Operations:
|
|||||||
As
reported
|
$
|
.35
|
$
|
.63
|
|||
Pro
forma
|
$
|
.33
|
$
|
.59
|
|||
Net
Income:
|
|||||||
As
reported
|
$
|
60,223
|
$
|
109,079
|
|||
Add: Stock-based employee compensation expense included in reported
net
income, net of tax
|
454
|
870
|
|||||
Deduct: Total stock-based employee compensation expense determined
under
the fair-
value-based method
for all awards, net of tax
|
(3,796
|
)
|
(7,678
|
)
|
|||
Pro
forma
|
$
|
56,881
|
$
|
102,271
|
|||
Basic
Earnings per Share:
|
|||||||
As
reported
|
$
|
.37
|
$
|
.68
|
|||
Pro
forma
|
$
|
.35
|
$
|
.63
|
|||
Diluted
Earnings per Share:
|
|||||||
As
reported
|
$
|
.37
|
$
|
.67
|
|||
Pro
forma
|
$
|
.35
|
$
|
.63
|
8.
|
Defined
Benefit Pension Plans
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||
(In thousands) |
July
1,
2006
|
|
July
2,
2005
|
|
July
1,
2006
|
|
July
2,
2005
|
||||||
Service
Cost
|
$
|
1,478
|
$
|
1,764
|
$
|
2,909
|
$
|
3,460
|
|||||
Interest
Cost on Benefit Obligation
|
3,670
|
3,349
|
7,207
|
6,570
|
|||||||||
Expected
Return on Plan Assets
|
(3,087
|
)
|
(2,752
|
)
|
(6,068
|
)
|
(5,554
|
)
|
|||||
Recognized
Net Actuarial Loss
|
928
|
636
|
1,823
|
1,281
|
|||||||||
Amortization
of Prior Service Costs
|
45
|
—
|
89
|
—
|
|||||||||
$
|
3,034
|
$
|
2,997
|
$
|
5,960
|
$
|
5,757
|
9.
|
Swap
Arrangement
|
10.
|
Warranty
Obligations
|
Six
Months Ended
|
|||||||
(In thousands) |
July
1,
2006
|
July
2,
2005
|
|||||
Beginning
Balance
|
$
|
33,453
|
$
|
27,369
|
|||
Provision
charged to income
|
21,209
|
11,915
|
|||||
Usage
|
(18,230
|
)
|
(10,856
|
)
|
|||
Acquisitions
(divestitures)
|
(62
|
)
|
6,002
|
||||
Adjustments
to previously provided warranties, net
|
(1,151
|
)
|
(1,603
|
)
|
|||
Other,
net (a)
|
1,107
|
(1,951
|
)
|
||||
Ending
Balance
|
$
|
36,326
|
$
|
30,876
|
(a)
|
Primarily
represents the effects of currency
translation.
|
11.
|
Restructuring
and Other Costs, Net
|
(In thousands) |
Life
and
Laboratory
Sciences
|
Measurement
and
Control
|
Other
|
Corporate
|
Total
|
|||||||||||
Cost of Revenues
|
$
|
1,266
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
1,266
|
||||||
Restructuring and Other Costs, Net
|
2,571
|
2,094
|
7
|
108
|
4,780
|
|||||||||||
$
|
3,837
|
$
|
2,094
|
$
|
7
|
$
|
108
|
$
|
6,046
|
(In thousands) |
Life
and
Laboratory
Sciences
|
Measurement
and
Control
|
Other
|
Corporate
|
Total
|
Cost of Revenues
|
$
|
1,266
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
1,266
|
||||||
Restructuring and Other Costs, Net
|
5,617
|
2,634
|
9
|
114
|
8,374
|
|||||||||||
$
|
6,883
|
$
|
2,634
|
$
|
9
|
$
|
114
|
$
|
9,640
|
11.
|
Restructuring
and Other Costs, Net (continued)
|
11.
|
Restructuring
and Other Costs, Net (continued)
|
(In thousands) |
Severance
|
Employee
Retention
(a)
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
|||||||||||
Pre-2005
Restructuring Plans
|
||||||||||||||||
Balance
at December 31, 2005
|
$
|
1,249
|
$
|
—
|
$
|
8,114
|
$
|
589
|
$
|
9,952
|
||||||
Costs
incurred in 2006 (b)
|
12
|
—
|
732
|
54
|
798
|
|||||||||||
Reserves
reversed
|
—
|
—
|
(491
|
)
|
—
|
(491
|
)
|
|||||||||
Payments
|
(702
|
)
|
—
|
(1,422
|
)
|
(76
|
)
|
(2,200
|
)
|
|||||||
Currency
translation
|
50
|
—
|
208
|
1
|
259
|
|||||||||||
Balance
at July 1, 2006
|
$
|
609
|
$
|
—
|
$
|
7,141
|
$
|
568
|
$
|
8,318
|
||||||
2005
Restructuring Plans
|
||||||||||||||||
Balance
at December 31, 2005
|
$
|
6,132
|
$
|
313
|
$
|
1,131
|
$
|
357
|
$
|
7,933
|
||||||
Costs
incurred in 2006 (b)
|
5,430
|
85
|
764
|
632
|
6,911
|
|||||||||||
Reserves
reversed
|
(387
|
)
|
—
|
(177
|
)
|
—
|
(564
|
)
|
||||||||
Payments
|
(8,798
|
)
|
(259
|
)
|
(993
|
)
|
(845
|
)
|
(10,895
|
)
|
||||||
Currency
translation
|
431
|
6
|
38
|
—
|
475
|
|||||||||||
Balance
at July 1, 2006
|
$
|
2,808
|
$
|
145
|
$
|
763
|
$
|
144
|
$
|
3,860
|
||||||
2006
Restructuring Plans
|
||||||||||||||||
Costs
incurred in 2006 (b)
|
$
|
2,191
|
$
|
58
|
$
|
—
|
$
|
132
|
$
|
2,381
|
||||||
Payments
|
(431
|
)
|
—
|
—
|
(132
|
)
|
(563
|
)
|
||||||||
Balance
at July 1, 2006
|
$
|
1,760
|
$
|
58
|
$
|
—
|
$
|
—
|
$
|
1,818
|
(a) |
Employee-retention
costs are accrued ratably over the period through which employees
must
work to qualify for a payment.
|
(b)
|
Excludes
a net gain of $0.5 million in the Life and Laboratory Sciences segment
on
the sale of abandoned assets and the disposal of a product line and
a gain
of $0.2 million in the Measurement and Control segment on the disposal
of
product lines.
|
12.
|
Litigation
|
12.
|
Litigation
(continued)
|
13.
|
Discontinued
Operations
|
Three
Months Ended
|
Six
Months Ended
|
||||||||||||||||||||||||
(Dollars in thousands) |
July
1, 2006
|
July
2, 2005
|
July
1, 2006
|
July
2., 2005
|
|||||||||||||||||||||
Life
and Laboratory Sciences
|
$
|
539,286
|
75.6%
|
|
$
|
487,462
|
74.6%
|
|
$
|
1,051,641
|
75.2%
|
|
$
|
880,767
|
72.6%
|
|
|||||||||
Measurement
and Control
|
174,182
|
24.4%
|
|
166,159
|
25.4%
|
|
346,114
|
24.8%
|
|
332,062
|
27.4%
|
|
|||||||||||||
$
|
713,468
|
100%
|
|
$
|
653,621
|
100%
|
|
$
|
1,397,755
|
100%
|
|
$
|
1,212,829
|
100%
|
|
(a)
|
The
company maintains allowances for doubtful
accounts for estimated losses resulting from the inability of its
customers to pay amounts due. Such allowances totaled $22.5 million
at
July 1, 2006. The company estimates the amount of customer receivables
that are uncollectible based on the age of the receivable, the
creditworthiness of the customer and any other information that is
relevant to the judgment. If the financial condition of the company’s
customers were to deteriorate, reducing their ability to make payments,
additional allowances would be
required.
|
(b)
|
The
company writes down its inventories for estimated obsolescence for
differences between the cost and estimated net realizable value taking
into consideration usage in the preceding 12 months, expected demand
and
any other information that is relevant to the judgment. If ultimate
usage
or demand vary significantly from expected usage or demand, additional
writedowns may be required.
|
(c)
|
The
company periodically evaluates goodwill for impairment using forecasts
of
discounted future cash flows. Goodwill totaled $1.99
billion at July 1, 2006. Estimates of future cash flows require
assumptions related to revenue and operating income growth, asset-related
expenditures, working capital levels and other factors. Different
assumptions from those made in the company’s analysis could materially
affect projected cash flows and the company’s evaluation of goodwill for
impairment. Should the fair value of the company’s goodwill decline
because of reduced operating performance, market declines, or other
indicators of impairment, or as a result of changes in the discount
rate,
charges for impairment of goodwill may be
necessary.
|
(d)
|
The
company estimates the fair value of acquisition-related intangible
assets
principally based on projections of cash flows that will arise from
identifiable intangible assets of acquired businesses. The projected
cash
flows are discounted to determine the present value of the assets
at the
dates of acquisition.
Actual
cash flows arising from a particular intangible asset could vary
from
projected cash flows which could imply different carrying values
and
annual amortization expense from those established at the dates
of
acquisition.
|
(e)
|
The
company reviews other long-lived assets for impairment when indication
of
potential impairment exists, such as a significant reduction in cash
flows
associated with the assets. Other long-lived assets totaled $905.2
million at July 1, 2006, including $283.2 million of fixed assets.
In
testing a long-lived asset for impairment, assumptions are made concerning
projected cash flows associated with the asset. Estimates of future
cash
flows require assumptions related to revenue and operating income
growth
and asset-related expenditures associated with the asset being reviewed
for impairment. Should future cash flows decline significantly from
estimated amounts, charges for impairment of other long-lived assets
may
be necessary.
|
(f)
|
In
instances where the company sells equipment with a related installation
obligation, the company generally recognizes revenue related to the
equipment when title passes. The company recognizes revenue related
to the
installation when it performs the installation. The allocation of
revenue
between the equipment and the installation is based on relative fair
value
at the time of sale. Should the fair value of either the equipment
or the
installation change, the company’s revenue recognition would be affected.
If fair value is not available for any undelivered element, revenue
for
all elements is deferred until delivery is
completed.
|
(g)
|
In
instances where the company sells equipment with customer-specified
acceptance criteria, the company must assess whether it can demonstrate
adherence to the acceptance criteria prior to the customer’s acceptance
testing to determine the timing of revenue recognition. If the nature
of
customer-specified acceptance criteria were to change or grow in
complexity such that the company could not demonstrate adherence,
the
company would be required to defer additional revenues upon shipment
of
its products until completion of customer acceptance testing.
|
(h)
|
The
company’s software license agreements generally include multiple products
and services, or “elements.” The company recognizes software license
revenue based on the residual method after all elements have either
been
delivered or vendor specific objective evidence (VSOE) of fair value
exists for any undelivered elements. In the event VSOE is not available
for any undelivered element, revenue for all elements is deferred
until
delivery is completed. Revenues from software maintenance and support
contracts are recognized on a straight-line basis over the term of
the
contract. VSOE of fair value of software maintenance and support
is
determined based on the price charged for the maintenance and support
when
sold separately. Revenues from training and consulting services are
recognized as services are performed, based on VSOE, which is determined
by reference to the price customers pay when the services are sold
separately.
|
(i)
|
At
the time the company recognizes revenue, it provides for the estimated
cost of product warranties and returns based primarily on historical
experience and knowledge of any specific warranty problems that indicate
projected warranty costs may vary from historical patterns. The liability
for warranty obligations of the company’s continuing operations totaled
$36.3
million at July 1, 2006. Should product failure rates or the actual
cost
of correcting product failures vary from estimates, revisions to
the
estimated warranty liability would be
necessary.
|
(j)
|
The
company estimates the degree to which tax assets and loss carryforwards
will result in a benefit based on expected profitability by tax
jurisdiction, and provides a valuation allowance for tax assets and
loss
carryforwards that it believes will more likely than not go unused.
If it
becomes more likely than not that a tax
asset or loss carryforward will be used, the company reverses the
related
valuation allowance with an offset generally to goodwill as most
of the
tax attributes arose from acquisitions. The company’s tax valuation
allowance totaled $65.5 million at July 1, 2006. Should the company’s
actual future taxable income by tax jurisdiction vary from estimates,
additional allowances or reversals thereof may be
necessary.
|
(k)
|
The
company provides a liability for future income tax payments in the
worldwide tax jurisdictions in which it operates. Accrued income
taxes
totaled $21.9 million at July 1, 2006. Should tax return positions
that
the company expects are sustainable not be sustained upon audit,
the
company could be required to record an incremental tax provision
for such
taxes. Should previously unrecognized tax benefits ultimately be
sustained, a reduction in the company’s tax provision would
result.
|
(l)
|
The
company estimates losses on contingencies and litigation for which
a loss
is probable and provides a reserve for losses that can be reasonably
estimated. Should the ultimate losses on contingencies and litigation
vary
from estimates, adjustments to those reserves may be
required.
|
(m)
|
One
of the company’s U.S. subsidiaries and several non-U.S. subsidiaries
sponsor defined benefit pension plans. Major assumptions used in
the
accounting for these employee benefit plans include the discount
rate,
expected return on plan assets and rate of increase in employee
compensation levels. Assumptions are determined based on company
data and
appropriate market indicators in consultation with third party actuaries,
and are evaluated each year as of the plans’ measurement date. Net
periodic pension costs for defined benefit plans totaled $16.1 million
in
2005
and the company’s unfunded benefit obligation totaled $124 million at
year-end 2005. Should any of these assumptions change, they would
have an
effect on net periodic
pension costs and the unfunded benefit obligation. For example, a
10%
decrease in the discount rate would result in an annual increase
in
pension expense of approximately $3 million and an increase in the
benefit
obligation of approximately $31
million.
|
(n)
|
The
fair value of each stock option granted by the company is
estimated using the Black-Scholes option pricing model. Use of
a valuation
model requires management to make certain assumptions with respect
to
selected model inputs. Management estimates expected volatility
based on the historical volatility of the company’s stock.
The expected life of a grant is estimated using the simplified method
for “plain vanilla” options as permitted by SAB 107. The risk-free
interest rate is based on U.S. Treasury zero-coupon issues with
a
remaining term which
approximates the expected life assumed at the date of grant. Changes
in these input variables would affect the amount of expense
associated with stock-based compensation. The compensation
expense recognized for all equity-based awards is net of estimated
forfeitures. The company estimates forfeiture rates based
on historical analysis of option forfeitures. If actual
forfeitures should vary from estimated forfeitures, adjustments
to
compensation expense may be
required.
|
(o)
|
The
company records restructuring charges for the cost of vacating
facilities
based on future lease obligations and expected sub-rental income.
The
company’s accrued restructuring costs for abandoned facilities in
continuing operations totaled $7.9 million at July 1, 2006.
Should actual
cash flows associated
with sub-rental income from vacated facilities vary from estimated
amounts, adjustments may be required.
|
(p)
|
The
company estimates the expected proceeds from any assets held for
sale and,
when necessary, records losses to reduce the carrying value of these
assets to estimated realizable value. Should the actual or estimated
proceeds, which would include post-closing purchase price adjustments,
vary from current estimates, results could differ from expected
amounts.
|
Three
Months Ended
|
|||||||
July
1,
2006
|
July
2,
2005
|
||||||
Consolidated
|
10.1%
|
|
8.1%
|
|
Three
Months Ended
|
||||||||||
(Dollars in thousands) |
July
1,
2006
|
July
2,
2005
|
Change | |||||||
Revenues
|
$
|
539,286
|
$
|
487,462
|
10.6%
|
|
||||
Operating
Income Margin
|
11.6%
|
|
10.1%
|
|
1.5
|
|||||
Cost
of revenues charges
|
0.2%
|
|
2.3%
|
|
(2.1)
|
|
||||
Restructuring
and other costs (income), net
|
0.5%
|
|
0.0%
|
|
0.5
|
|||||
Stock
option compensation expense
|
0.5%
|
|
0.0%
|
|
0.5
|
|||||
Amortization
of acquisition-related intangible assets
|
4.5%
|
|
3.6%
|
|
0.9
|
|||||
Adjusted
Operating Income Margin
|
17.3%
|
|
16.0%
|
|
1.3
|
Three
Months Ended
|
||||||||||
(Dollars in thousands) |
July
1,
2006
|
July
2,
2005
|
Change |
Revenues
|
$
|
174,182
|
$
|
166,159
|
4.8%
|
|
||||
Operating
Income Margin
|
11.8%
|
|
7.3%
|
|
4.5
|
|||||
Cost
of revenues charges
|
0.0%
|
|
0.1%
|
|
(0.1)
|
|
||||
Restructuring
and other costs, net
|
1.2%
|
|
1.3%
|
|
(0.1)
|
|
||||
Stock
option compensation expense
|
0.4%
|
|
0.0%
|
|
0.4
|
|||||
Amortization
of acquisition-related intangible assets
|
0.8%
|
|
0.8%
|
|
0.0
|
|||||
Adjusted
Operating Income Margin
|
14.2%
|
|
9.5%
|
|
4.7
|
Six
Months Ended
|
|||||||
July
1,
2006
|
July
2,
2005
|
||||||
Consolidated
|
10.0%
|
|
9.3%
|
|
Six
Months Ended
|
||||||||||
(Dollars in thousands) |
July
1,
2006
|
July
2,
2005
|
Change | |||||||
Revenues
|
$
|
1,051,641
|
$
|
880,767
|
19.4%
|
|
||||
Operating
Income Margin
|
11.3%
|
|
11.5%
|
|
(0.2)
|
|
||||
Cost
of revenues charges
|
0.1%
|
|
1.3
%
|
|
(1.2)
|
|
||||
Restructuring
and other costs (income), net
|
0.6%
|
|
(0.2)%
|
|
0.8
|
|||||
Stock
option compensation expense
|
0.5%
|
|
0.0
%
|
|
0.5
|
|||||
Amortization
of acquisition-related intangible assets
|
4.6%
|
|
2.7
%
|
|
1.9
|
|||||
Adjusted
Operating Income Margin
|
17.1%
|
|
15.3
%
|
|
1.8
|
Six
Months Ended
|
||||||||||
(Dollars in thousands) |
July
1,
2006
|
July
2,
2005
|
Change |
Revenues
|
$
|
346,114
|
$
|
332,062
|
4.2%
|
|
||||
Operating
Income Margin
|
12.2%
|
|
9.2%
|
|
3.0
|
|||||
Cost
of revenues charges
|
0.0%
|
|
0.1%
|
|
(0.1)
|
|
||||
Restructuring
and other costs, net
|
0.8%
|
|
0.9%
|
|
(0.1)
|
|
||||
Stock
option compensation expense
|
0.4%
|
|
0.0%
|
|
0.4
|
|||||
Amortization
of acquisition-related intangible assets
|
0.8%
|
|
0.6%
|
|
0.2
|
|||||
Adjusted
Operating Income Margin
|
14.2%
|
|
10.8%
|
|
3.4
|
· |
finding
new markets for our products;
|
· |
developing
new applications for our technologies;
|
· |
combining
sales and marketing operations in appropriate markets to compete
more
effectively;
|
· |
allocating
research and development funding to products with higher growth prospects;
|
· |
continuing
key customer initiatives;
|
· |
expanding
our service offerings;
|
· |
strengthening
our presence in selected geographic markets; and
|
· |
continuing
the development of commercial tools and infrastructure to increase
and
support cross-selling opportunities of products and services to take
advantage of our breadth in product
offerings.
|
· |
if
we are unable to successfully combine the businesses of Thermo and
Fisher
in a manner that permits the combined company to achieve the cost
savings
and operating synergies anticipated to result from the merger, such
anticipated benefits of the merger may not be realized fully or at
all or
may take longer to realize than
expected;
|
· |
lost
sales and customers as a result of certain customers of either of
the two
companies deciding not to do business with the combined
company;
|
· |
complexities
associated with managing the combined
businesses;
|
· |
integrating
personnel from diverse corporate cultures while maintaining focus
on
providing consistent, high quality products and customer
service;
|
· |
potential
unknown liabilities and unforeseen increased expenses or delays associated
with the merger; and
|
· |
performance
shortfalls at one or both of the two companies as a result of the
diversion of management’s attention to the
merger
|
· |
being
required, under certain circumstances under the merger agreement,
to pay a
termination fee of $200 million to
Fisher;
|
· |
having
to pay certain costs relating to the merger, such as legal, accounting,
financial advisor and printing fees (approximately $7.3 million of
which
were capitalized at July 1,
2006); and
|
· |
the
focus of management on the merger instead of on pursuing other
opportunities that could have been beneficial to
Thermo,
|
· |
the
Consolidated Interest Coverage Ratio (the ratio of Consolidated EBITDA
to
Consolidated Interest Expense) for any period of four consecutive
fiscal
quarters to be less than 3.25:1.00;
or
|
· |
the
Consolidated Total Debt to Consolidated Total Capitalization ratio
at the
end of any fiscal quarter to be greater than
0.50:1.00.
|
Period |
Total
Number
of
Shares
Purchased
|
Average
Price
Paid
per Share
|
Total
Number
of
Shares
Purchased
as
Part of
Publicity
Announced
Plans
or
Programs
(1)
|
Maximum
Dollar
Amount
of
Shares That May Yet be Purchased
Under
the
Plans
or
Programs
(1)
|
|||||||||
April
2 - April 29
|
—
|
$
|
—
|
—
|
$
|
100,000,000
|
|||||||
April
30 - May 27
|
2,750,747
|
36.78
|
2,750,747
|
198,824,000
|
|||||||||
May
28 - July 1
|
3,500,000
|
36.24
|
3,500,000
|
72,000,000
|
|||||||||
Total
Second Quarter
|
6,250,747
|
$
|
36.48
|
6,250,747
|
$
|
72,000,000
|
(1)
|
On
February 28, 2006, the company announced a repurchase program authorizing
the purchase of up to $100 million of the company’s common stock in the
open market or in negotiated transactions.
On
May 7, 2006, the company increased the existing authorization for
the
purchase of up to an additional $200 million of the company’s common stock
in the open market or in negotiated transactions, which expires February
28, 2007. All of the shares of common stock repurchased by the company
during the second quarter of 2006 were purchased under this
program.
|
Nominee
|
For
|
Withheld
|
|||||
Peter
J. Manning
|
86,889,526
|
60,964,275
|
|||||
Jim
P. Manzi
|
86,895,675
|
60,958,126
|
|||||
Elaine
S. Ullian
|
86,935,859
|
60,917,942
|
|
For |
Against
|
Abstained
|
|||||||
146,605,807
|
398,598
|
849,395
|
|
For |
Against
|
Abstained
|
|||||||
57,586,004
|
75,553,735
|
1,988,717
|
THERMO
ELECTRON CORPORATION
|
|
/s/
Peter M. Wilver
|
|
Peter
M. Wilver
|
|
Vice
President and Chief Financial Officer
|
|
/s/
Peter E. Hornstra
|
|
Peter
E. Hornstra
|
|
Corporate
Controller and Chief Accounting
Officer
|
Exhibit
Number
|
Description
of Exhibit
|
2.1
|
Agreement
and Plan of Merger by and among Thermo Electron Corporation, Trumpet
Merger Corporation and Fisher Scientific International Inc., dated
as of
May 7, 2006 (filed as Exhibit 2.1 to the company’s Current Report on Form
8-K dated May 7, 2006 [File No. 1-8002] and incorporated in this
document
by reference).
|
|
10.1
|
Marijn
E. Dekkers Waiver Letter, dated as of May 7, 2006 (filed as Exhibit
10.1
to the company’s Current Report on Form 8-K dated May 7, 2006 [File No.
1-8002] and incorporated in this document by
reference).
|
|
10.2
|
Thermo
Electron Corporation Directors Stock Option Plan, as amended and
restated
as of May 18, 2006 (filed as Exhibit 10.1 to the company’s Current Report
on Form 8-K dated May 18, 2006 [File No. 1-8002] and incorporated
in this
document by reference).
|
|
31.1
|
Certification
of Chief Executive Officer required by Exchange Act Rules 13a-14(a)
and
15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of
2002.
|
|
31.2
|
Certification
of Chief Financial Officer required by Exchange Act Rules 13a-14(a)
and
15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of
2002.
|
|
32.1
|
Certification
of Chief Executive Officer required by Exchange Act Rules 13a-14(b)
and
15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of
2002.*
|
|
32.2
|
Certification
of Chief Financial Officer required by Exchange Act Rules 13a-14(b)
and
15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of
2002.*
|
*
|
Certification
is not deemed “filed” for purposes of Section 18 of the Exchange Act, or
otherwise subject to the liability of that section. Such
certification is not deemed to be incorporated by reference into
any
filing under the Securities Act or the Exchange Act, except to the
extent
that the registrant specifically incorporates it by
reference.
|